Tempus AI lawsuit filed against company for alleged securities fraud.

A class action lawsuit has been filed against Tempus AI, Inc. (NASDAQ: TEM) by Pomerantz LLP. The lawsuit alleges that Tempus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Investors who purchased or acquired Tempus securities during the Class Period can request to be appointed as Lead Plaintiff until August 12, 2025. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

A class action lawsuit has been filed against Tempus AI, Inc. (NASDAQ: TEM) by Pomerantz LLP, alleging that Tempus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Investors who purchased or acquired Tempus securities between August 6, 2024, and May 27, 2025, are encouraged to participate in the lawsuit. The deadline to request appointment as Lead Plaintiff is August 12, 2025. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

The lawsuit alleges that Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded. Additionally, it claims that the credibility and substance of Tempus' joint venture with SoftBank was at risk due to the appearance of "round-tripping" capital to create revenue for Tempus. Furthermore, the complaint alleges that Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability. AstraZeneca is also alleged to have reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement between it, Tempus, and Pathos AI. These issues are said to have revealed weakness in core operations and revenue prospects, leading to materially false and misleading statements about Tempus' business, operations, and prospects [1][2][3].

The price of Tempus common stock fell significantly following the release of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which raised numerous red flags over Tempus' management, operations, and financial reporting. The stock price fell more than 19% on that day [1][2].

Investors who suffered substantial losses are encouraged to participate in the class action lawsuit. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit and can select a law firm of their choice to litigate the case. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff [2].

References:
[1] https://www.morningstar.com/news/pr-newswire/20250731la41466/tempus-ai-inc-tem-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit
[2] https://www.globenewswire.com/news-release/2025/08/06/3127995/0/en/AUGUST-11-DEADLINE-Tempus-AI-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit-RGRD-Law.html
[3] https://www.globenewswire.com/news-release/2025/08/03/3126254/9788/en/TEM-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Tempus-AI-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html